Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer immunology research

• Publication date

  2013-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-13-0007PMID 24777501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multimodal Imaging and Detection Strategy With 124 I-Labeled Chimeric Monoclonal Antibody cG250 for Accurate Localization and Confirmation of Extent of Disease During Laparoscopic and Open Surgical Resection of Clear Cell Renal Cell Carcinoma

  2013cited by this paper
• Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

  2013cited by this paper
• Potential role of 124 I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

  2012cited by this paper
• Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

  2012cited by this paper
• Role of Gamma Knife surgery in patients with 5 or more brain metastases.

  2012cited by this paper
• Immunocytokines: a novel class of potent armed antibodies.

  2012cited by this paper
• Bone Marrow Dosimetry Using 124I-PET

  2012cited by this paper
• Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies

  2012cited by this paper
• Antibody-cytokine fusion proteins.

  2012cited by this paper
• Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

  2012cited by this paper
• Radiolabeled antibodies for cancer imaging and therapy.

  2012cited by this paper
• Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging

  2012cited by this paper
• Interfering with pH regulation in tumours as a therapeutic strategy

  2011cited by this paper
• Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250

  2011cited by this paper
• Emerging role of immunoPET in receptor targeted cancer therapy.

  2011cited by this paper
• Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

  2011influential reference
• 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET

  2011cited by this paper
• A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

  2011cited by this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Positive Progress in ImmunoPET—Not Just a Coincidence

  2010cited by this paper
• EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

  2010cited by this paper
• [Multidisciplinary management of brain metastases].

  2010cited by this paper
• The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

  2010cited by this paper
• Antibody-based vascular tumor targeting.

  2010cited by this paper
• Radioimmunotherapy (RIT) with 131l-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial.

  2010cited by this paper
• ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).

  2010cited by this paper
• Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.

  2009influential reference
• Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma.

  2009cited by this paper
• 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy

  2009cited by this paper
• Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients

  2009cited by this paper
• Potent antibody drug conjugates for cancer therapy.

  2009cited by this paper
• Bispecific T-cell engaging antibodies for cancer therapy.

  2009cited by this paper
• Radioiodination of peptide hormones and immunoglobulin preparations: comparison of the chloramine T and iodogen method.

  2009cited by this paper
• Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems

  2008influential reference
• Brain metastases: current management and new developments

  2008cited by this paper
• Chemotherapy for brain metastases in small-cell lung cancer.

  2008cited by this paper
• Immuno-PET: a navigator in monoclonal antibody development and applications.

  2007cited by this paper
• Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

  2007cited by this paper
• Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin

  2007cited by this paper
• Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function.

  2007cited by this paper
• Multidisciplinary management of brain metastases.

  2007cited by this paper
• Whole brain radiotherapy for the treatment of multiple brain metastases.

  2006cited by this paper
• Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

  2006cited by this paper
• Whole-brain radiotherapy in the management of brain metastasis.

  2006cited by this paper
• Radiotherapeutic management of brain metastases: a systematic review and meta-analysis.

  2005cited by this paper
• OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

  2005cited by this paper
• Tumour vascular targeting

  2005cited by this paper
• Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy

  2005cited by this paper
• Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate

  2005cited by this paper
• Symptom response after palliative radiotherapy for patients with brain metastases.

  2002cited by this paper
• Management of brain metastases

  2002cited by this paper
• Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin

  2002cited by this paper
• Management of brain metastases.

  1999cited by this paper
• Management of single brain metastasis: a practice guideline

  1997cited by this paper
• A formula to estimate the approximate surface area if height and weight be known. 1916.

  1989cited by this paper
• A formula to estimate the approximate surface area if height and weight be known

  1989cited by this paper

• Imaging-guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines.

  2026cites this paper
• Past, present and future of drug conjugates for cancer therapy

  2025cites this paper
• Immunotherapy in central nervous system tumors

  2025cites this paper
• CIMT 2025: Report on the 22nd Annual Meeting of the Association for Cancer Immunotherapy

  2025cites this paper
• Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein

  2025cites this paper
• A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors

  2024cites this paper
• Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy

  2024cites this paper
• Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells

  2024cites this paper
• An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade

  2024cites this paper
• Cytokine Biopharmaceuticals with "Activity-on-Demand" for Cancer Therapy.

  2024cites this paper
• Brain Metastasis: an insight into novel molecular targets for theranostic approaches.

  2024cites this paper
• Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen

  2023cites this paper
• [Combination of internal and external beam radiotherapy].

  2023cites this paper
• Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma

  2023cites this paper
• Antibody-based radiopharmaceuticals as theranostic agents: an overview.

  2022cites this paper
• Delivery of radioimmunotherapy for solid tumors

  2022cites this paper
• Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine

  2022cites this paper
• Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives

  2021cites this paper
• Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy.

  2021cites this paper
• Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice

  2021cites this paper
• Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances.

  2021cites this paper
• Theranostics in Brain Tumors.

  2021cites this paper
• Combination radionuclide therapy: A new paradigm.

  2021cites this paper
• Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124

  2021cites this paper
• Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography

  2021cites this paper
• Imaging the host response to cancer

  2021cites this paper
• Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

  2021cites this paper
• Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18.

  2020cites this paper
• Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

  2020influential citation
• The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

  2020influential citation
• A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo

  2020cites this paper
• Immunocytokines are a promising immunotherapeutic approach against glioblastoma

  2020cites this paper
• Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

  2020cites this paper
• VCAM-1 targeted alpha-particle therapy for early brain metastases

  2019cites this paper
• Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.

  2019cites this paper
• Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity

  2019cites this paper
• Introduction à l'imagerie par Tomographie d'Émission de Positons : définitions, approches de reconstruction et initiation aux isotopes complexes.

  2019cites this paper
• Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

  2019influential citation
• Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases

  2019cites this paper
• A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

  2019cites this paper
• A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas

  2019cites this paper
• Joining Forces: Prospects for Targeted Radionuclide Therapy in Combined-Modality Regimens

  2018cites this paper
• TGF-β induces oncofetal fibronectin that, in turn, modulates TGF-β superfamily signaling in endothelial cells

  2018cites this paper
• Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery.

  2018cites this paper
• Drug Conjugates Specific to Carbonic Anhydrase IX for Cancer Therapy

  2018cites this paper
• Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases

  2018cites this paper
• Aligning physics and physiology: Engineering antibodies for radionuclide delivery.

  2018cites this paper
• Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.

  2018cites this paper
• Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry

  2018cites this paper
• Targeting Fibronectin for Cancer Imaging and Therapy.

  2017cites this paper
• First-in-Man Evaluation of 124I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment

  2017cites this paper
• EDB Fibronectin-Specific SPECT Probe 99mTc-HYNIC-ZD2 for Breast Cancer Detection

  2017cites this paper
• Linker stability influences the anti‐tumor activity of acetazolamide‐drug conjugates for the therapy of renal cell carcinoma

  2017cites this paper
• Targeted radionuclide therapy in combined-modality regimens.

  2017cites this paper
• Nanotrastuzumab in combination with radioimmunotherapy: Can it be a viable treatment option for patients with HER2-positive breast cancer with brain metastasis?

  2016cites this paper
• Radiolabeled Antibody‐Based Imaging in Clinical Oncology

  2016cites this paper
• Antibody-drug conjugates: Current status and future perspectives.

  2016cites this paper
• Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma

  2016cites this paper
• Novel Radiopharmaceuticals for Therapy

  2016cites this paper
• Fibronectin-targeted drug delivery in cancer.

  2016cites this paper
• Advances in decoding breast cancer brain metastasis

  2016cites this paper
• Assessment of a fully 3D Monte Carlo reconstruction method for preclinical PET with iodine-124

  2015cites this paper
• Development of PET probes for cancer imaging.

  2015cites this paper
• Planning Combined Treatments of External Beam Radiation Therapy and Molecular Radiotherapy

  2015cites this paper
• Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.

  2015cites this paper
• In vivo imaging with antibodies and engineered fragments.

  2015cites this paper
• Développement de fragments d’anticorps ciblant ZnT8 pour l’imagerie fonctionnelle des cellules bêta pancréatiques

  2015cites this paper
• Noninternalizing targeted cytotoxics for cancer therapy.

  2015cites this paper
• New approaches for imaging and therapy of solid cancer.

  2015cites this paper
• Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.

  2014cites this paper
• Based on Maytansinoids Drug Conjugates − Curative Properties of Noninternalizing Antibody

  2014cites this paper
• Non-Internalizing Antibody-Drug Conjugates for Cancer Therapy

  2014cites this paper
• Planning Combined Treatments of External Beam Radiation Therapy and Molecular Radiotherapy

  2014influential citation
• Recent advances in osteosarcoma.

  2014cites this paper
• From target discovery to clinical trials with armed antibody products.

  2014cites this paper
• Therapeutic Cancer Vaccines Targeting Molecules Associated with Tumor Angiogenesis

  2014cites this paper
• Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use

  2013cites this paper
• Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure.

  2013cites this paper